Nanologica Q1 2025: Limited near-term visibility but sales ramp up to be expected in H2 - Redeye
Bildkälla: Stockfoto

Nanologica Q1 2025: Limited near-term visibility but sales ramp up to be expected in H2 - Redeye

Redeye updates its outlook on Nanologica, continuing to anticipate a considerable sales ramp-up in H2. Although limited near-term visibility weighs on the share price—currently trading in line with our bear case—we argue the case remains solid, supported by multiple catalysts.

Redeye updates its outlook on Nanologica, continuing to anticipate a considerable sales ramp-up in H2. Although limited near-term visibility weighs on the share price—currently trading in line with our bear case—we argue the case remains solid, supported by multiple catalysts.
Börsvärldens nyhetsbrev
ANNONSER